Medorion’s AI-powered SaaS Health Behavior Management platform leverages behavioral science and predictive models to analyze the barriers behind people’s health decisions, offering health organizations a more effective way to drive with patients towards better adherence
TEL AVIV, Israel, December 01, 2021--(BUSINESS WIRE)--Medorion (https://medorion.com/), a SaaS-solution provider enabling healthcare organizations to create, manage, and measure personalized health persuasion plans, wins Pfizer’s Vaccines Global Innovation Challenge, which was launched to find innovative approaches that address both patient education and access to vaccination.
Having developed the world’s preferred COVID-19 vaccine shot, Pfizer has proved itself a dedicated player in its mission of ensuring medical centers worldwide have access to life-saving vaccines, while patients have easy access to information and education on their importance. Higher risk groups require effective, non abrasive communications between medical authorities, health plans, providers administrators, medical personnel, and various information channels in order to safely remain inline with crucial vaccine guidelines and protect themselves. Moreover, communications that address personal barriers are much more likely to influence decision-making and much less likely to create abrasion, which could prove instrumental in, for instance, achieving better vaccination outcomes.
As part of the Vaccines Global Innovation Challenge, Pfizer challenged the tech medical sector to firstly explore innovation in Information and Education, particularly for adolescents and adult populations that could potentially benefit from staying up-to-date on various recommended vaccines. Secondly, the challenge required participants to identify the means by which appropriate patients gain access to recommended vaccines. Each finalist was given the opportunity to pitch their presentation in front of a live audience at the Frontiers Health conference, which was accompanied by spirited panel discussions.
Pfizer recognised the potential of Medorion’s aim to help organizations drive better health outcomes through the process of health behavior management and taking steps that help change patients behavior across entire populations. By developing a SaaS platform that combines behavioral science with AI capabilities, the company has proved itself an important vehicle in reaching diverse, large-scale audiences with personal relevant information for each patient. Utilizing these behavior-based insights, Medorion’s persuasion software provides health organizations with an in-depth understanding of patients' concerns regarding medications, vaccines, treatments, and checkups. Medorion’s behavioral persuasion then automates omni-channel one-on-one patient interactions at scale, positively transforming their health decisions while improving health delivery and financial outcomes.
"We’re extremely proud to be selected from a host of other promising solutions," says Asaf Kleinbort, CEO of Medorion. " To have received such a major stamp of approval from one of the world’s leading bio-pharmaceutical companies that has contributed so much to fighting the pandemic of our time adds credence to our journey and reinforces our conviction in addressing the more human element of medicine."
"Medorion presented a unique capability using behavioral science to generate insights around patient’s health decisions," says Jim Mangione, External Partnerships Lead at Pfizer. "We’re looking forward to exploring the application of these insights to help with patient education and awareness around vaccines."
Founded in 2017, Medorion's behavioral intelligence software provides health insurers with an in-depth understanding of members and their concerns, enhancing health plans in all areas pertaining to human behavior. Utilizing behavior-based insights, the company’s platform enables health plan members to personalize and automate one-on-one member conversations at scale, facilitating proactive interactions that improve health delivery and financial outcomes. Used by top US health insurers, Medorion has improved Star Ratings, raised preventative service utilization, improved medication adherence, and boosted member retention and acquisition rates. The company is effectively helping organizations manage the entire process of health management more efficiently and take strides that will change medical behavior across entire populations and improve the lives of millions of individuals. For more information, visit https://medorion.com/
About Pfizer Inc.
Pfizer Inc. is a research-based global biopharmaceutical company engaged in the discovery, development, manufacture, marketing, sales, and distribution of biopharmaceutical products. Its global portfolio includes medicines and vaccines. The Company works across markets to develop wellness, prevention, treatments and cures. It collaborates with healthcare providers, governments and local communities to support and provide access to healthcare. Its medicines and vaccines provide value for healthcare providers and patients, through treatment of diseases, improvements in health, wellness. It sells its prescription pharmaceutical products to wholesalers, retailers, hospitals, clinics, government agencies and pharmacies. In the United States, it sells its vaccines products to the federal government, centers for disease control and prevention (CDC), wholesalers, individual provider offices, retail pharmacies and integrated delivery networks. For more information, visit https://www.pfizer.com/
View source version on businesswire.com: https://www.businesswire.com/news/home/20211201005928/en/
ReBlonde for Medorion